For the first time, scientists have 'photographed' a rare plasma instability, where high-energy electron beams form into spaghetti-like filaments. A new study, published in Physical Review Letters ...

More than two dozen people rallied on Monday against a new for-profit clinic in Whitby that pays people for plasma donations. Demonstrators marched outside the office of the Grifols Plasma ...

After four days, Mobile World Congress has come to an end. During our time in Barcelona, we saw countless phones, wearables, AI implementations and gadgets on display.

GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

One of the last big phar­ma hold­outs in obe­si­ty has now en­tered what has be­come the most sought-af­ter field in the in­dus­try.

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

Partnership marks AbbVie’s entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global ...

The outlay, plus up to $1.87 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra. As a major player in the medical ...

Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for ...